Vascular Pharmaceuticals

Vascular Pharmaceuticals (VPI) is a Delaware C-Corporation headquartered in Chapel Hill, North Carolina. Founded in 2005, the company is a small business with four employees and generates approximately $1 million in annual revenue. VPI focuses on the development of novel therapies for diabetic nephropathy, a serious complication of diabetes. Their lead product, VPI-2690B, is a humanized monoclonal antibody (mAb) currently in a Phase 2 clinical trial. This therapy targets the C-loop domain sequence within the αVβ3 receptor, aiming to restore normal receptor activation and address pathologic changes associated with diabetic nephropathy. VPI's approach distinguishes itself through its focus on a unique molecular target, the αVβ3 receptor. Their research suggests that inhibiting ligand binding to this receptor with VPI-2690B can effectively normalize abnormal αVβ3 activation, leading to improvements in diabetic nephropathy-related issues. For further information, please visit vascularpharma.com.